Association of Cytomegalovirus (CMV) DNAemia With Long-Term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients

被引：10

作者：

Kumar, Lakshin ^{[1
]}

Dasgupta, Sayan ^{[2
]}

Murray-Krezan, Cristina ^{[3
]}

Singh, Nina ^{[4
,5
]}

Rakita, Robert M. ^{[1
]}

Fisher, Cynthia E. ^{[1
,6
]}

Limaye, Ajit P. ^{[1
]}

机构：

[1] Univ Washington, Dept Med, Div Allergy & Infect Dis, 1959 NE Pacific St, Seattle, WA 98195 USA

[2] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA USA

[3] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA

[4] VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA

[5] Univ Pittsburgh, Pittsburgh, PA USA

[6] Univ Washington, 1959 NE Pacific St, Seattle, WA 98195 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2024年 / 78卷 / 03期

基金：

美国国家卫生研究院;

关键词：

liver transplant; immunocompromised host; viral infections; cytomegalovirus; antiviral therapy;

D O I：

10.1093/cid/ciad643

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In a post-hoc analysis of the association of CMV DNAemia with long-term mortality in a randomized trial of CMV preemptive therapy vs. antiviral prophylaxis in D+R- liver transplant recipients, post-intervention CMV DNAemia was associated with increased mortality after adjusting for study arm. Graphical Abstract This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/association-of-cmv-dnaemia-with-long-term-mortality-in-a-randomized-trial-of-preemptive-therapy-pet-and-antiviral-prophylaxis-ap-for-prevention-of-cmv-disease-in-high-risk-donor-seropositive-recipient-se-2480b1a4-e573-43a6-973b-94ea264eed04

引用

页码：719 / 722

页数：4

共 50 条

[41] The Best Method for CMV Prevention in High-risk Kidney Transplant Recipients? Either, per National Norwegian Transplant Database: Commentary on Blom et al, Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management
Kotton, Camille Nelson
TRANSPLANTATION, 2023, 107 (08) : 1671 - 1672
[42] Pre-emptive ganciclovir therapy based on PCR compared with prophylaxis for prevention of CMV disease in high risk liver transplant recipients.
de Vera, M
Smallwood, GA
Davis, L
Stieber, A
Thomas, H
TRANSPLANTATION, 2000, 69 (08) : S407 - S407
[43] The devil is in the details: Nuances of pre-emptive therapy for cytomegalovirus disease prevention in high-risk seropositive donors liver transplant recipients
Heldman, Madeleine R.
Limaye, Ajit P.
TRANSPLANT INFECTIOUS DISEASE, 2024, 26 (03)
[44] Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients
Winston, DJ
Busuttil, RW
TRANSPLANTATION, 2003, 75 (02) : 229 - 233
[45] Increasing Proportion of High-Risk Cytomegalovirus ( CMV) Donor Positive/recipient Negative (D plus R-) Serostatus in Solid Organ Transplant Recipients (SOTRs)
Imlay, H.
Wagener, M. M.
Singh, N.
Limaye, A. P.
AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 761 - 761
[46] RANDOMIZED COMPARISON OF GANCICLOVIR AND HIGH-DOSE ACYCLOVIR FOR LONG-TERM CYTOMEGALOVIRUS PROPHYLAXIS IN LIVER-TRANSPLANT RECIPIENTS
WINSTON, DJ
WIRIN, D
SHAKED, A
BUSUTTIL, RW
LANCET, 1995, 346 (8967): : 69 - 74
[47] Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management
Blom, Kjersti B.
Birkeland, Grete K.
Midtvedt, Karsten
Jenssen, Trond G.
Reisaeter, Anna V.
Rollag, Halvor
Hartmann, Anders
Sagedal, Solbjorg
Sjaastad, Ivar
Tylden, Garth
Njolstad, Gro
Nilsen, Einar
Christensen, Andreas
Asberg, Anders
Birkeland, Jon A.
TRANSPLANTATION, 2023, 107 (08) : 1846 - 1853
[48] Cytomegalovirus Post-Prophylaxis Surveillance in High-Risk Kidney and Liver Recipients Prevents CMV End-Organ Disease and Ganciclovir-Resistance
Jorgenson, Margaret R.
Meyer, Ethan
Leverson, Glen E.
Descourouez, Jillian L.
Saddler, Christopher M.
Smith, Jeannina A.
Rice, John P.
Mandelbrot, Didier A.
Odorico, Jon S.
CLINICAL TRANSPLANTATION, 2024, 38 (09)
[49] Prevention of CMV disease in pediatric kidney transplant recipients: Evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients
Renoult, Edith
Clermont, Marie-Jose
Phan, Veronique
Buteau, Chantal
Alfieri, Carolina
Tapiero, Bruce
PEDIATRIC TRANSPLANTATION, 2008, 12 (04) : 420 - 425
[50] Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection
Winston, DJ
Imagawa, DK
Holt, CD
Kaldas, F
Shaked, A
Busuttil, RW
TRANSPLANTATION, 1995, 60 (11) : 1357 - 1360

← 1 2 3 4 5 →